Continuing Medication for Opioid Use Disorder After Release From Jail or Prison

Release from jail or prison is one of the highest-risk moments in the life of a person with an opioid use disorder, and it is also one of the most preventable. Opioid tolerance falls during any extended period of reduced or interrupted use. Someone who returns to the amount they once used before incarceration may be facing a far narrower margin than their body can handle. Public health agencies, including the Centers for Disease Control and Prevention, have repeatedly identified the period immediately following release as a time of markedly elevated overdose risk.

The encouraging part is that this risk is well understood and responds to planning. Medication for opioid use disorder, started or continued without a gap at the moment of release, is among the most effective protections available. What follows is a practical look at how that continuity works, what tends to break it, and what to line up before the release date rather than after.

Why the Weeks After Release Carry Elevated Risk

Several pressures converge at once. Tolerance is lower. Housing may be unsettled. Old contacts and familiar locations reappear, often within hours. Identification documents, a phone, and transportation may all need to be replaced before a person can even attend an appointment. Meanwhile the practical demands stack up quickly: reporting to a probation or parole officer, looking for work, reconnecting with children or family members, and finding somewhere stable to sleep.

Against that backdrop, a treatment appointment three weeks out is easy to miss, not because the person is unmotivated but because the first days after release absorb everything. This is why continuity planning treats the release date itself as the target, not the week that follows it.

The Approved Medications and What They Do

There are three medications approved in the United States for treating opioid use disorder: methadone, buprenorphine, and naltrexone. They are not interchangeable, and they work in meaningfully different ways. The American Society of Addiction Medicine maintains a national practice guideline covering their clinical use, and the National Institute on Drug Abuse publishes general research summaries on their effectiveness.

Methadone and buprenorphine are both opioid medications that reduce cravings and withdrawal without producing the cycle associated with problematic use. Methadone for opioid use disorder is dispensed through federally regulated opioid treatment programs, which means access depends on there being such a program within reach. Buprenorphine can be prescribed by licensed prescribers in general medical settings, which often makes it easier to arrange in a community clinic or primary care office.

Naltrexone works differently. It blocks opioid effects rather than substituting for them, and the extended-release injectable form requires a period without opioids before the first dose so that withdrawal is not triggered. That timing requirement matters a great deal in a reentry context, because it can sometimes be satisfied during incarceration but is much harder to arrange afterward.

Which medication fits depends on clinical history, other health conditions, what is locally available, and the person’s own preference. That last factor is not a courtesy. A medication someone is willing to keep taking generally protects them better than one they abandon. Specific dosing is a matter for the treating clinician and is not something to plan from an article.

What Continuity Actually Requires

Continuity is less about a single decision than about a short list of concrete items being in place before the gate opens. In practice that means an identified community provider who has agreed to accept the person, a first appointment scheduled for the day of release or the next business day, a bridge supply or a same-day prescription arrangement so there is no interval without medication, a copy of the medication records from the facility, and a plan for how the person will physically get to that first appointment.

Facilities vary widely in whether they offer these medications at all and in how they handle transitions. Some initiate treatment during incarceration and coordinate a handoff. Others do not offer medication, and some discontinue it on intake. Availability differs by state and by individual facility, so the only reliable approach is to ask directly about that specific facility rather than assume a general standard applies.

If a discharge planner, reentry coordinator, or case manager is available, that person is the most useful contact to find early. Where no such role exists, families often end up assembling the plan themselves. Anyone trying to identify community providers can search the treatment locator maintained by the Substance Abuse and Mental Health Services Administration, or call 866-644-7911 to talk through what options exist in a given area.

If the Facility Did Not Offer Medication

Not being on medication at release does not close the door, though it does change the sequence. An assessment shortly after release can determine what is appropriate, and starting buprenorphine or methadone does not require a period of abstinence first. Naltrexone does. Because of the tolerance question, the first appointment being days rather than weeks out genuinely matters.

Some people leaving incarceration also need a medically supervised withdrawal period, particularly where alcohol or benzodiazepines are part of the picture rather than opioids alone. Understanding how medically supervised detox works, and where it fits relative to ongoing care, helps in evaluating what a program is actually proposing.

Insurance and Coverage After Release

Coverage is one of the most common places these plans stall. In many states Medicaid enrollment is suspended or terminated during incarceration, and reinstatement is not always immediate. A person can be clinically ready and provider-matched and still hit a delay because coverage has not been reactivated.

The practical response is to begin the coverage question well before release rather than treating it as paperwork to sort out later. Some jurisdictions have processes for initiating reinstatement in advance, and some providers will see a patient while an application is pending. Asking a prospective provider directly how they handle patients whose coverage is still being reinstated is worth doing early, because the answer varies considerably.

Building the Rest of the Plan Around the Medication

Medication addresses cravings and physiological risk. It does not by itself resolve housing instability, employment gaps, court obligations, or strained family relationships, and it is not a cure for the underlying disorder. Recovery is a process that unfolds over time rather than a threshold someone crosses on release day.

Counseling, peer support, and structured programming address the parts medication does not, and the appropriate intensity depends on individual circumstances. Reviewing the levels of care used in addiction treatment clarifies what the options look like in practice. For someone managing parole appointments and a job search simultaneously, an intensive outpatient schedule is sometimes more sustainable than a residential placement, though that tradeoff depends heavily on housing stability and on what the person is returning to.

It is also worth naming that a return to use is common and is not evidence that treatment has failed or that a person lacks resolve. What matters is how quickly someone reconnects with care afterward. A plan that anticipates this and specifies in advance who to call tends to work better than one that assumes a straight line.

What Families Can Do

Families often hold the only continuous view across a fragmented system, and that vantage point is useful. Helpful contributions tend to be concrete: making calls to providers during business hours when the person cannot, holding copies of medication records, arranging transportation to a first appointment, and keeping naloxone accessible at home.

It also helps to keep expectations proportionate to the first few weeks. Immediate employment, full repair of old conflicts, and complete stability are a lot to ask of anyone in that window. Attending appointments and staying on medication is the reasonable near-term goal.

Overdose Safety and When to Call for Help

Given the elevated risk at release, naloxone should be part of every plan. It reverses opioid overdose, is available without a prescription in the United States, and works only if someone nearby has it and knows how to use it. More than one person in the household should know where it is kept.

If an overdose is suspected, call 911 immediately. Naloxone can wear off before the opioid does, so emergency care is necessary even when someone appears to recover. For thoughts of suicide or self-harm, or for a mental health crisis, the 988 Suicide and Crisis Lifeline is reachable by calling or texting 988 in the United States. If someone is in immediate danger, call 911 or go to the nearest emergency department.

Questions Worth Asking Before Release

A few direct questions surface most of the gaps: Does this facility offer medication for opioid use disorder, and is the person currently receiving it? Who handles the handoff to a community provider? Is a first appointment scheduled, and for what date? Will there be medication available covering the interval between release and that appointment? Has Medicaid reinstatement been started? Who is the named contact if something falls through in the first week?

Vague answers to these are worth pressing on before release rather than after. For help thinking through options or locating providers in a particular area, call 866-644-7911.

The Short Version

The window after release is high risk, and it is also highly responsive to preparation. Uninterrupted medication, an appointment within days rather than weeks, active coverage, naloxone on hand, and one named person to call when something goes wrong will address most of what commonly goes wrong. None of it requires anything unusual. It mostly requires being arranged before the release date rather than improvised afterward.

This article is for general educational purposes and does not constitute medical advice, legal advice, or a substitute for clinical assessment by a qualified professional. Treatment decisions, including those involving medication, should be made with a licensed clinician who knows the full history. The Treatment Specialist is a national information resource and directory and does not provide treatment.